Ozempic

AllianceBernstein: Investors are getting ahead of themselves about healthcare

Antidiabetic drugs such as Ozempic have markets excited about healthcare, but AllianceBernstein’s Vinay Thapar calls for caution amongst the hype

March 13, 2024

Search portfolio Adviser

Sponsored by iShares

Ready to rethink your portfolio? Putting cash to work with bond ETFs

About Us
Cookie policy
Privacy policy
Acceptable use policy
Terms and conditions
Contact

LinkedIn

Published by MA Financial Media Ltd (part of Mark Allen),
St Jude’s Church, London SE24 0PB . Copyright (c) 2024.

Portfolio Adviser is a monthly news magazine and daily news web site aimed at wealth managers , investment IFAs and other professional fund pickers and asset allocators in the UK and Channel Islands. No news, articles or content may be reproduced in part or in full without express permission of Portfolio Adviser.

Ozempic

AllianceBernstein: Investors are getting ahead of themselves about healthcare

Ready to rethink your portfolio? Putting cash to work with bond ETFs